Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
NCT03971162Completed
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of conbercept in myopic choroidal neovascularization (mCNV) (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Best Corrected Visual Acuity change at 12 months. Started Jun 2019; status: completed.
02
Drugs
conbercept
03
Conditions
myopic choroidal neovascularization (mCNV)
Beyond the preview
Go deeper on NCT03971162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971162.